[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"left-ventricular-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:left-ventricular-dysfunction":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,51,76,105,127,159,223,255,305,339,368,392,415,440],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100638696","pascal-precision-gdmt-registry-100638696",false,"NCT07578129","PASCAL Precision-GDMT Registry","Improvement in Guideline-Directed Medical Therapy After Tricuspid Transcatheter Edge-to-Edge Repair in Participants With Reduced Left Ventricular Function","PASCAL","Inclusion Criteria:\n\n* Participants of age ≥ 18 years\n* ≥ severe tricuspid regurgitation\n* LVEF \\\u003C 50%\n* Written informed consent of the patient or her\u002Fhis legal representative\n* Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up\n* Planned follow-up within a dedicated heart failure clinic as part of routine care.\n\nExclusion Criteria:\n\n* Anatomy unsuitable for TEER as determined by local heart team\n* severe mitral regurgitation (defined as an EROA\\>40 mm2) treated (surgically or percutaneously) less than 3 months prior\n* severe left ventricular dysfunction (defined as an LVEF \\\u003C20%)\n* systolic pulmonary artery pressure \\>70 mmHg (right heart catheterization)\n* prior tricuspid valve intervention\n* severe leaflet degeneration or tricuspid valve anatomy precluding successful device placement\n* primary tricuspid valve disease\n* COPD requiring home oxygen therapy\n* active endocarditis, or recent episode within 4 weeks of discontinuation of antibiotic therapy\n* participants with unstable hemodynamic condition\n* significant co-morbidities resulting in an expected less than 12-month life expectancy\n* The presence of other anatomic or comorbid conditions or other medical, social or psychological conditions that in the investigators' opinion could limit the subject's ability to participate in the clinical study and its follow-up.\n* Participants under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision\n* Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to demonstrate that successful tricuspid valve repair with the PASCAL Precision System in participants with at least severe tricuspid insufficiency and left ventricular dysfunction will be associated with an improvement in up-titration of guideline-directed medical therapy (GDMT). The main question it aims to answer is:\n\nDoes the tricuspid insufficiency repair with the Pascal Precision System increases the dose of the medications used for heart failure therapy in the study population 12 months after tricuspid repair, as compared to the dose taken at baseline.\n\nParticipants undergoing tricuspid repair and fulfilling all inclusion\u002Fexclusion criteria will be asked to answer heart failure assessment as well as quality of life questionnaires at baseline and at 12 months post intervention. Medication monitoring will be performed throughout the study.",[26,27,28,29,30,31],"Tricuspid Insufficiency","Tricuspid Regurgitation (TR)","Left Ventricular Cardiac Dysfunction","Left Ventricular (LV) Systolic Dysfunction","Left Ventricular Dysfunction","Left Ventricular Ejection Fraction",[33,34,35,36,37,38],"T-TEER","Severe Tricuspid regurgitation","left ventricular dysfunction","GDMT score","NHYA","KCCQ","NOT_YET_RECRUITING","2026-05-11",{"date":42,"type":43},"2026-05-13","ACTUAL",{"date":45,"type":21},"2026-08-01",{"date":47,"type":21},"2027-08-31",{"name":49,"class":50},"Ceric Sàrl","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100611577","menopausal-hormone-therapy-and-left-ventricular-function-100611577","NCT07242391","Menopausal Hormone Therapy And Left Ventricular Function","Menopausal Hormone Therapy And Neural Control Of Left Ventricular Function","Inclusion Criteria\n\n• \\>45-60\\\u003C years of age\n\nExclusion Criteria\n\n* Male sex\n* Females between STRAW+10 stages -5 and 0\n* PMF in STRAW+10 stage +2\n* PMF using oral hormone therapy\n* Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)\n* Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction\n* Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.\n* Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.\n* Pregnancy\n* COPD\n* Diabetes\n* CKD\n* Raynaud's phenomenon\n* Sleep disorders\n* Shift workers\n* BMI ≥40.0kg\u002Fm2\n* Use of nicotine-containing products within the two years preceding study visits\n* Active cancer treatment","FEMALE","45 Years","60 Years",{"count":20,"type":21},"The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.",[64,30],"Menopause","2026-04-22",{"date":67,"type":43},"2026-04-23",{"date":69,"type":21},"2026-07",{"date":71,"type":21},"2027-12",{"name":73,"class":74},"Mayo Clinic","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100561787","the-jenavalve-align-ar-lvad-registry-100561787","NCT06594705","The JenaValve ALIGN-AR LVAD Registry","Transcatheter Aortic Valve Replacement Using the JenaValve TrilogyTM Heart Valve System for Clinically Significant Aortic Regurgitation in Patients With Left Ventricular Assist Devices (LVAD)","JENA-VAD","Inclusion Criteria:\n\n1. Subjects \\>=18 years of age with continuous flow LVAD (cfLVAD) with clinically significant AR1 leading to cfLVAD dysfunction using cfLVAD ASE guidelines that utilize contemporary management strategies for measurement of AR in patients with cfLVAD2,3:\n\n   • AR is graded from 0 to 6 (0 = none; 1 = trace; 2 = mild; 3 = mild-to-moderate; 4 = moderate; 5 = moderate-to-severe; 6 = severe). Considering that AR during continuous flow LVAD (cfLVAD) support is generally both systolic and diastolic, AR is deemed significant if graded ≥ 3.1\n2. Patient with NYHA functional class III\u002FIV\n3. Patient with high risk for SAVR as documented by Heart Team.\n4. Patient has suitable anatomy to accommodate the insertion and delivery of the JenaValve Trilogy™ Heart Valve System\n5. Patient or the patient's legal representative has provided written informed consent\n6. Patient or the patient's legal representative agrees to comply with all required post-procedure follow-up visits\n\nExclusion Criteria:\n\n1. Congenital uni- or bicuspid (Sievers 0) aortic valve morphology\n2. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant\n3. Mitral regurgitation \\> moderate\n4. Clinically significant coronary artery disease (CAD) requiring revascularization within 30 days prior to index procedure, or planned CAD revascularization procedure within 12 months after index procedure\n5. Echocardiographic or CT evidence of left ventricular or aortic valve thrombus\n6. Ongoing sepsis or active infective endocarditis with ongoing antibiotic (including suppressive) therapy or positive blood cultures within 6 weeks\n7. Hypertrophic cardiomyopathy with or without obstruction\n8. Severe pulmonary hypertension (systolic PA pressure \\>80 mmHg)\n9. Decompensated right heart failure as assessed clinically and, if available, by baseline right heart catheterization hemodynamics (e.g., right atrial pressure \\> pulmonary capillary wedge pressure and cardiac index \\\u003C 2.5 L\u002Fmin\u002Fm2\n10. Severe RV dysfunction as assessed clinically and by echocardiography\n11. Aortic annular diameter of \\\u003C21.0 mm or \\> 28.6 mm (assessed by Multi-detector CT measurement)\n12. Aortic annulus angulation \\> 70° (assessed by Multi-detector CT measurement)\n13. Straight length of ascending aorta of \\\u003C 55 mm\n14. Significant disease of ascending aorta, including ascending aortic aneurysm (defined as maximal luminal diameter of 50 mm or greater) or atheroma (including if thick \\[\\>5 mm\\], protruding or ulcerated)\n15. Myocardial infarction \\\u003C 30 days prior to index procedure\n16. Cerebrovascular event (TIA, stroke) \\\u003C 180 days prior to index procedure\n17. Blood dyscrasias as defined: leukopenia (WBC \\\u003C 3000\u002Fmm³), or thrombocytopenia (platelets \\\u003C 90,000\u002Fμl) or anemia (Men: Hgb \\\u003C 8.1 g\u002Fdl; Women: Hgb \\\u003C 7.4 g\u002Fdl)\n18. Active peptic ulcer or upper gastrointestinal bleeding \\\u003C 90 days prior to index procedure\n19. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be premedicated\n20. Subject unable to undergo pre-procedure transesophageal echocardiography or Multi-Detector CT (MDCT) scan for aortic annular sizing\n21. Patient is enrolled in another investigational medical device or drug study which has not completed the required primary endpoint follow-up. (Note: Patients involved in a long-term surveillance phase of another study are eligible for enrollment in this registry)",{"count":20,"type":21},"INTERVENTIONAL",[87],"NA","To evaluate the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR) who are indicated for TAVR",[90,91,92,93,30],"Aortic Regurgitation","Aortic Valve Insufficiency","Aortic Insufficiency","Aortic Valve Disease","RECRUITING","2026-03-30",{"date":97,"type":43},"2026-04-01",{"date":99,"type":43},"2024-12-09",{"date":101,"type":21},"2027-08",{"name":103,"class":50},"JenaValve Technology, Inc.",15,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":75},"100455286","london-valvular-heart-disease-and-reduced-ejection-fraction-detection-in-a-multi-ethnic-community-using-cardiac-ultrasound-100455286","NCT05208567","London Valvular Heart Disease and Reduced Ejection Fraction Detection in a Multi-ethnic Community Using Cardiac Ultrasound","LOVE","Inclusion Criteria:\n\n\\- Greater or equal to 65 years old\n\nExclusion Criteria:\n\n* Clinical diagnosis of Alzheimer's Disease or Vascular Dementia\n* Palliative Care patients.","65 Years",{"count":114,"type":21},500,"Heart Valve Disease and Heart failure contribute to 25% of hospital emergency admissions while heart failure alone has become one of the most common causes for hospitalisation in people over the age of 65. The burden of disease is likely to be high in a multi-ethnic community but there is a paucity of data. Management of heart valve disease requires appropriate surveillance and timely surgery. Similarly heart failure management requires treatment with medications aimed at slowing prevention of symptoms and preventing premature death. The NHS long term plan priorities early detection and treatment of valve disease and heart failure in order to reduce the burden on emergency services and improve the health of the population.\n\nDiagnosis is made using cardiac ultrasound, however staff with the required skills-set are critically limited in the community.\n\nThe investigators will train non-expert staff within primary care to perform abbreviated cardiac ultrasound to detect heart valve disease or heart failure. This will be opportunistic scanning to reduce healthcare footfall.\n\nAll scans will be reviewed by an expert and the investigators will use the anonymised data to develop machine learning tools to begin working with academic partners to develop tools that can improve the reliability of diagnosis from ultrasound.\n\nThe investigators hope to identify the proportion with the above conditions in a multi-ethnic community and assess the feasibility of developing a program where staff can be trained for community detection, streamlined referrals can be created bridging the gap between primary and secondary care, reducing hospital emergency admissions, while ensuring patients are managed optimally.",[117,30],"Heart Valve Diseases","2026-02-19",{"date":120,"type":43},"2026-02-23",{"date":122,"type":43},"2023-03-14",{"date":124,"type":21},"2026-09-02",{"name":126,"class":74},"Queen Mary University of London",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":85,"phases":136,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":75},"100497961","phase-3-dapagliflozine-to-attenuate-cardiac-remodeling-after-acute-myocardial-infarction-100497961","NCT05764057","DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","DAPAPROTECTOR","Inclusion Criteria:\n\n* Age ≥18 years;\n* STEMI (e.g., ST elevation above the J-point of ≥0.1 millivolt in ≥two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with LV dysfunction (LVEF ≤45%); after completion of PCI or angiography procedure\n* eGFR ≥ 25 mL\u002FMin per 1.73m²;\n* Systolic blood pressure (SBP) before first dosing \\>100 mmHg and\u002For Diastolic blood pressure (DBP) \\>70 mmHg before first dosing;\n* Ability to provide written informed consent and willing to participate in the 6-month follow-up period.\n* Affiliation to a national health care system (AME are not allowed).\n\nExclusion Criteria:\n\n* Cardiogenic shock (SBP \\\u003C90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization;\n* Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);\n* Any other form of diabetes than diabetes type 2\n* History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption);\n* \\>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea;\n* Acute symptomatic urinary tract infection (UTI) or genital infection at the time of randomization;\n* Concomitant treatment (and\u002For within the 4 weeks prior to the baseline visit) with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin)\n* Echocardiographic examination of insufficient quality to permit adequate analysis of the study end-points.\n* Impossibility to evaluate cardiac remodeling using TTE (e.g., pacemaker or defibrillator …);\n* Atrial fibrillation rhythm at randomization;\n* Life expectancy \\\u003C6 month;\n* Known pregnancy at time of randomization;\n* Breastfeeding women\n* Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)\n* Current participation in another interventional trial. Patients under guardianship or curatorship",{"count":135,"type":21},450,[137],"PHASE3","Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction.\n\nPreventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and cardiovascular death, is likely to translate into benefit in reducing clinical events in post-MI patients.",[140,141,142,30],"AMI","STEMI","NSTEMI",[144,145,146,147,148,149],"Acute myocardial infarction","Left ventricular dysfunction","Dapagliflozin","Transthoracic echocardiography","Cardiac remodeling","Cardiovascular Intensive Care Unit (CICU)","2025-12-12",{"date":152,"type":43},"2025-12-19",{"date":154,"type":43},"2023-06-12",{"date":156,"type":21},"2026-10-12",{"name":158,"class":74},"Assistance Publique - Hôpitaux de Paris",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":17,"minAge":168,"maxAge":18,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":190,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":75},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State",true,"7 Years",{"count":170,"type":21},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[173,174,30,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189],"Hypertension","Left Ventricular Hypertrophy","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Diseases","Kidney Injury","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria",[191,192,173,193,194,174,189,195,196,197,198,199,200,201,202,203,204,205,206,207,176,178,208,209,187,210,211,212,213],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram","2025-12-04",{"date":216,"type":43},"2025-12-11",{"date":218,"type":43},"2021-05-19",{"date":220,"type":21},"2026-12",{"name":222,"class":74},"Wake Forest University Health Sciences",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":75},"100614948","assement-of-left-ventricular-function-before-decannulation-in-cardiac-surgery-visual-estimation-vs-tee-100614948","NCT07286227","Assement of Left Ventricular Function Before Decannulation in Cardiac Surgery :Visual Estimation vs TEE","Assessment of Left Ventricular Function Before Decannulation in Cardiopulmonary Bypass Surgeries: Comparison of the Cardiac Surgeon's Visual Estimation and Transesophageal Echocardiography","LVFuncTee","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Scheduled for elective cardiac surgery requiring cardiopulmonary bypass (CABG, valve surgery, or aortic surgery)\n* ASA physical status III-IV\n* Able and willing to provide written informed consent\n* Suitable for intraoperative transesophageal echocardiography (TEE)\n\nExclusion Criteria:\n\n* Emergency surgery\n* Known severe preoperative left ventricular dysfunction (EF \\\u003C 30%)\n* Significant arrhythmias (e.g., atrial fibrillation)\n* Preoperative requirement for mechanical circulatory support (e.g., IABP)\n* Contraindications to TEE (esophageal pathology, bleeding risk, strictures)\n* Inability to provide informed consent","75 Years",{"count":233,"type":21},70,"This study aims to evaluate the diagnostic performance of the cardiovascular surgeon's visual estimation of LV function before decannulation following cardiopulmonary bypass, using TEE results as the reference standard.",[236,30],"Cardiopulmonary Bypass Surgery",[238,31,239,240,241,242,243,244,245],"Transesophageal Echocardiography","Visual Estimation","Eyeballing Method","Cardiac Surgery","Ejection Fraction Assessment","Intraoperative Monitoring","Decannulation","Cardiopulmonary Bypass","2025-12-03",{"date":248,"type":43},"2025-12-16",{"date":250,"type":21},"2026-01-01",{"date":252,"type":21},"2026-12-02",{"name":254,"class":74},"Ataturk University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":265,"conditions":266,"keywords":290,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":75},"100435439","prevalence-and-risk-factors-associated-with-cardiac-comorbidity-in-psoriasis-100435439","NCT04950218","Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA: Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA","Inclusion Criteria:\n\n* Patients 18 years or older with a diagnosis of psoriasis will be invited to participate\n\nExclusion Criteria:\n\n* Patients not able to cooperate to the study\n* Patients unable understand and sign informed consent",{"count":264,"type":21},1000,"In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.",[267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,30,283,284,285,286,287,288,289],"Psoriasis","Cardiovascular Diseases","Cardiovascular Risk Factor","Cardiovascular Pathology","Psoriasis Vulgaris","Psoriatic Nail","Psoriasis Face","Psoriasis Guttate","Psoriasis Gyrata","Psoriasis Diffusa","Psoriasis Palmaris","Psoriasis Annularis","Psoriasis Circinata","Psoriasis Plantaris","Psoriasis Universalis","Psoriasis Geographica","Myocardial Infarction","Myocardial Ischemia","Heart Failure","Stroke","Heart Diseases","Heart Failure, Systolic","Heart Failure, Diastolic",[267,291,292,293,294,295],"Echocardiography","Advanced echocardiography","Biomarkers","Mortality","Cardiovascular mortality","2025-09-09",{"date":298,"type":43},"2025-09-15",{"date":300,"type":43},"2021-09-01",{"date":302,"type":21},"2034-10-01",{"name":304,"class":74},"Herlev and Gentofte Hospital",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":85,"phases":316,"briefSummary":317,"conditions":318,"keywords":324,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":75},"100498344","conventional-biventricular-versus-left-bundle-branch-pacing-on-outcomes-in-heart-failure-patients-100498344","NCT05769036","Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients","Randomized Study of Integrated Evaluation of Conventional Biventricular and Left Bundle Branch Pacing Therapy Effect on Left Ventricular Remodeling and Clinical Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction","RECOVER-HF","Inclusion criteria:\n\n1. The patient is willing and able to comply with the protocol and has provided written informed consent;\n2. Male or female patients aged 18 to 80 years;\n3. Patients with ischemic or non-ischemic cardiomyopathy;\n4. Symptomatic HF for at least 3 months prior to enrollment in the study;\n5. New York Heart Association (NYHA) functional class HF ≥ II;\n6. Patients with HF in sinus rhythm (SR) with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with LBBB morphology;\n7. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration 130-149 ms with LBBB morphology;\n8. Patients with HF in SR with LVEF ≤ 35% (measured in the last 6 weeks prior to enrollment), QRS duration ≥150 ms with non-LBBB morphology;\n9. Patients with symptomatic persistent or permanent atrial fibrillation, HF with LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) and an uncontrolled heart rate who are candidates for atrioventricular junction ablation (irrespective of QRS duration);\n10. Patients with HF, LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) and indications for continuous ventricular pacing due to bradycardia;\n11. Patients who have received a conventional pacemaker or an implanted cardioverter-defibrillator and who subsequently develop symptomatic HF with LVEF \\\u003C 40% (measured in the last 6 weeks prior to enrollment) despite optimal medical therapy, and who have a significant proportion of right ventricle pacing;\n12. Optimal HF medical therapy.\n\nExclusion criteria:\n\n1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;\n2. Acute myocardial infarction within 3 months prior to enrollment;\n3. Acute coronary syndrome;\n4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);\n5. Patients listed for heart transplant;\n6. Patients with implanted cardiac assist device;\n7. Acute myocarditis;\n8. Infiltrative myocardial disease;\n9. Hypertrophic cardiomyopathy;\n10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;\n11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;\n12. Mental or physical inability to participate in the study;\n13. Patients unable or unwilling to cooperate within the study protocol;\n14. Patients with rheumatic heart disease;\n15. Mechanic tricuspid valve patients;\n16. Patients with any serious medical condition that could interfere with this study;\n17. Enrollment in another investigational drug or device study;\n18. Patients not available for follow-up;\n19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml\u002Fmin\u002F1.73 m2);\n20. Life expectancy ≤ 12 months;\n21. Participation in another telemonitoring concept.","80 Years",{"count":315,"type":21},60,[87],"Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of cardioresynchronization device using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Subsequently, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has showed greater improvement in hemodynamic parameters than with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to biventricular CRT. This method has become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS duration. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP in patients with CRT indications. However, it is not enough data about CRT with LBBP effectiveness in LV remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP compared with conventional biventricular CRT will significantly improve the clinical outcomes and reverse LV remodeling in patients with chronic HF with reduced LV ejection fraction and reduce the number of non-responders to conventional CRT.",[285,319,320,321,30,322,323],"Left Bundle-Branch Block","Ischemic Cardiomyopathy","Non-ischemic Dilated Cardiomyopathy","Left Ventricular Dyssynchrony","Left Ventricle Remodeling",[325,326,327,328,329],"Cardiac Resynchronization Therapy","Biventricular Pacing","Left Bundle Branch Pacing","Speckle Tracking Echocardiography","Biomarker of Fibrosis and Remodeling","2025-09-03",{"date":332,"type":43},"2025-09-10",{"date":334,"type":43},"2023-10-01",{"date":336,"type":21},"2028-09-01",{"name":338,"class":74},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":85,"phases":347,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":75},"100453721","phase-4-preoperative-maltodextrins-effect-on-cardiac-function-in-cardiac-surgery-100453721","NCT05188222","Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery","The Effect of Preoperative Maltodextrin on Cardiac Function in Cardiac Surgery Patients with Reduced Left Ventricular Ejection Fraction: a Randomized, Controlled, Double-blind, Clinical Trial","Inclusion Criteria:\n\n* 18 years of age or older\n* Presenting for coronary artery bypass grafting surgery\n* Preoperative left ventricular ejection fraction \\\u003C 50%\n* First case of the day (7:30am start time)\n\nExclusion Criteria:\n\n* Dysphagia, gastroparesis\n* Cannot tolerate oral intake\n* Celiac disease\n* Type 1 diabetes",{"count":233,"type":21},[348],"PHASE4","A randomized, controlled, double-blinded clinical trial evaluating the effect of the administration of a Maltodextrin solution on cardiac function in patients presenting for coronary artery bypass grafting surgery with a reduced left ventricular ejection fraction.",[30,351,352],"Quality of Recovery","Right Ventricular Dysfunction",[354,355,356,357,358],"Cardiac surgery","Insulin","Maltodextrin","Enhanced Recovery After Surgery","Quality of Recovery After Surgery","2025-02-21",{"date":361,"type":43},"2025-02-24",{"date":363,"type":21},"2025-12-01",{"date":365,"type":21},"2027-03-01",{"name":367,"class":74},"Jewish General Hospital",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":313,"enrollmentInfo":376,"targetDuration":4,"studyType":85,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":391,"locationsCount":75},"100497721","left-bundle-branch-pacing-on-outcomes-and-ventricular-remodeling-in-biventricular-crt-nonresponders-100497721","NCT05760924","Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders","Randomized Trial of Left Bundle Branch Pacing Effect on Clinical Outcomes and Left Ventricular Remodeling in Patients With Nonresponse to Biventricular Cardiac Resynchronization Therapy","RESCUE","Inclusion criteria:\n\n1. The patient is willing and able to comply with the protocol and has provided written informed consent;\n2. Male or female patients aged 18 to 80 years;\n3. Patients with ischemic or non-ischemic cardiomyopathy;\n4. Symptomatic HF for at least 3 months prior to enrollment in the study;\n5. New York Heart Association (NYHA) functional class HF ≥ II;\n6. Patients who are non-responders to biventricular CRT with HF, reduced LVEF and CRT-D replacement or one of the CRT-D leads replacement indications (without LVEF increase ≥ 5% and\u002For without a left ventricle end-systolic volume decrease ≥ 15% after CRT-D implantation at least 1 year old);\n7. Optimal HF medical therapy.\n\nExclusion criteria:\n\n1. Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;\n2. Acute myocardial infarction within 3 months prior to enrollment;\n3. Acute coronary syndrome;\n4. Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);\n5. Patients listed for heart transplant;\n6. Patients with implanted cardiac assist device;\n7. Acute myocarditis;\n8. Infiltrative myocardial disease;\n9. Hypertrophic cardiomyopathy;\n10. Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;\n11. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;\n12. Mental or physical inability to participate in the study;\n13. Patients unable or unwilling to cooperate within the study protocol;\n14. Patients with rheumatic heart disease;\n15. Mechanic tricuspid valve patients;\n16. Patients with any serious medical condition that could interfere with this study;\n17. Enrollment in another investigational drug or device study;\n18. Patients not available for follow-up;\n19. Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml\u002Fmin\u002F1.73 m2);\n20. Life expectancy ≤ 12 months;\n21. Participation in another telemonitoring concept.",{"count":377,"type":21},30,[87],"Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with the increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of device for cardiac resynchronization therapy using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Cardiac conduction system pacing is currently a promising technique for these patients. Particularly, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has shown greater improvement in hemodynamic parameters comparing with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP, especially high pacing threshold. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to conventional biventricular CRT. Also, since 2019, left bundle branch pacing-optimized CRT (LBBPO CRT) has been used in clinical practice. These methods have become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS complex duration on electrocardiogram. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP and LBBPO CRT in patients with CRT indications. However, it is not enough data about impact of CRT with LBBP and combined CRT with LBBP and LV pacing on myocardial remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP and combined CRT with LBBP and LV pacing compared with conventional biventricular pacing will significantly improve the clinical outcomes and reverse myocardial remodeling in patients who are non-responders to biventricular CRT with HF, reduced LV ejection fraction and with indications to CRT devices with defibrillator function (CRT-D) or one of the CRT-D leads replacement.",[285,319,320,321,30,323],[325,326,327,328,329,382,383,384],"Combined Left Bundle Branch and Left Ventricular Pacing","CRT Non-responder","CRT Responder","2024-11-20",{"date":387,"type":43},"2024-11-22",{"date":389,"type":43},"2024-11-01",{"date":336,"type":21},{"name":338,"class":74},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":400,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":85,"phases":403,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":75},"100469071","sodium-lowering-vascular-effects-trial-100469071","NCT05388032","Sodium Lowering Vascular Effects Trial","A Mechanistic Trial of Dietary Sodium Reduction on Vascular Structure and Function","SOLVE","Inclusion Criteria:\n\n* Men or women aged ≥40 years. Individuals \\\u003C40 years are at a low risk for clinical and subclinical CVD\n* Elevated BP or hypertension (systolic BP ≥120 mmHg and diastolic BP ≥80 mmHg with or without use of antihypertensive medications)\n\nExclusion Criteria:\n\n* Glomerular filtration rate (eGFR) \\\u003C30 or end-stage renal disease (kidney transplant or chronic dialysis)\n* History of cardiovascular disease\n* Shift worker or regularly work at night\n* Cancer requiring chemotherapy or radiation treatment in the previous two years\n* Current pregnancy or breastfeeding or plans to become pregnant during the study\n* Consumption of ≥21 alcoholic drinks\u002Fweek\n* Current participation in another lifestyle intervention or drug trial\n* Current residence or planned residence that makes it difficult to meet trial requirements\n* Other concerns regarding ability to meet trial requirements (at the discretion of the study coordinator)","40 Years",{"count":402,"type":21},256,[87],"The proposed mechanistic trial will test the effect of dietary sodium reduction on cardiac and vascular structure and function in those with elevated blood pressure or hypertension. Findings from this study will fill the knowledge gap on the underlying mechanisms of dietary sodium intake on cardiovascular disease risk in addition to blood pressure and could provide further evidence on sodium reduction for the prevention of cardiovascular disease.",[406,407,174,30],"Endothelial Dysfunction","Vascular Stiffness",{"date":387,"type":43},{"date":410,"type":43},"2023-01-25",{"date":412,"type":21},"2026-12-31",{"name":414,"class":74},"Tulane University",{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":85,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":75},"100522868","reducing-cognitive-impairment-by-management-of-heart-failure-as-a-modifiable-risk-factor-100522868","NCT06088212","Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor","Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor: the Cog-HF Trial","Cog-HF","Inclusion Criteria:\n\n1. Hospitalised with HF as primary or secondary diagnosis.\n2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge.\n\nExclusion Criteria:\n\n1. Unable to provide written consent; requiring palliative care; or participating in another RCT\n2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with \"true\" CI, any patients with a repeated MoCA\\>25 at 2 weeks post-discharge will be excluded.\n3. Terminal illness (eg. cancer) that may influence 12-month prognosis.",{"count":424,"type":21},168,[87],"This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.",[285,428,429,30,430,431],"Cognitive Impairment","Dementia","Cognitive Change","Cognitive Decline","2024-08-09",{"date":434,"type":43},"2024-08-12",{"date":436,"type":43},"2024-07-01",{"date":69,"type":21},{"name":439,"class":74},"Baker Heart and Diabetes Institute",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":85,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":469},"100543504","microvascular-dysfunction-assessment-to-predict-left-ventricular-reverse-remodeling-100543504","NCT06356727","Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling","Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling in Idiopathic Dilated Cardiomyopathy","MICROREV","Inclusion Criteria:\n\n* Male or female, aged \\>18 years\n* First diagnosis of idiopathic DCM (defined according to the most recent ESC Guidelines) with LVEF ≤ 40% and clinical indication to diagnostic coronary angiography\n* Willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Obstructive CAD (defined as angiographically intermediate disease \\[50%-70%\\] with impaired FFR or as angiographically severe disease \\[\\>70%\\] in 1 or more epicardial vessels)\n* History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery\n* Valvular heart disease (rheumatic heart disease, severe aortic stenosis, severe aortic regurgitation, severe primary mitral regurgitation)\n* Infective endocarditis\n* Congenital heart disease\n* Peripartum cardiomyopathy\n* Acute myocarditis (detected by endomyocardial biopsy - histological criteria - or by CMR - Lake Louis criteria) and pericarditis\n* Persistent tachyarrhythmias (documented persistent high-rate supraventricular arrhythmias)\n* Excessive alcohol intake (\\>80 g\u002Fdie for at least five years)\n* History of chemotherapy (anthracycline therapy, cumulative dosages \\>250 mg\u002Fm2)\n* History of uncontrolled arterial hypertension (blood pressure \\>160\u002F100 mmHg)\n* Stage IV and V of chronic kidney disease (eGFR \\\u003C 30 ml\u002Fmin, estimated through CKD - EPI Creatinine Equation)\n* Allergy or other contraindication to iodinated contrast and\u002For adenosine\n* Chronic resting O2 saturation \\\u003C85%\n* Pregnancy or suspected pregnancy","85 Years",{"count":450,"type":21},190,[87],"Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF \\\u003C40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.",[285,30,454],"Idiopathic Dilated Cardiomyopathy",[456,457,458,459],"coronary microvascular dysfunction","heart failure","left ventricular reverse remodeling","optimal medical therapy","2024-04-09",{"date":462,"type":43},"2024-04-10",{"date":464,"type":43},"2024-01-03",{"date":466,"type":21},"2030-01-31",{"name":468,"class":74},"Azienda Ospedaliera Universitaria Integrata Verona",9]